Science Corporation has successfully raised $400 million in a Series D funding round, bringing its valuation to $3.5 billion. This significant capital injection aims to support the company’s growth in its anti-blindness business, according to TechCrunch.
The funding round highlights investor confidence in Science Corporation’s mission and technology, positioning the company for accelerated development and market expansion. The capital will likely be used to scale operations and enhance product offerings in the vision care sector.
For Japanese investors and markets, this development underscores the growing global emphasis on healthcare innovation, particularly in vision-related technologies, which may influence investment trends within the region’s biotech and medtech sectors.
